A Study to Evaluate Claudin 18.2-Directed ADC LCB02A in Advanced Solid Tumors

This is a Phase 1/2 open label study consisting of dose escalation cohorts (Phase 1) followed by expansion cohorts (Phase 2). The Phase 1 dose escalation population includes subjects with advanced solid tumors that are refractory to standard of care therapy or for whom no standard of care options are available. Once the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of single agent LCB02A is determined, the study will proceed to Phase 2 expansion cohorts in selected tumor types.

NCT Number	NCT07460375
Lead Sponsor	LigaChem Biosciences, Inc. Collaborators: AntibodyChem Biosciences, Inc.
Conditions	Advanced Solid Tumors
Enrollment	191 participants
Start Date	2026-08
Primary Completion	2030-02 (estimated)
Study Completion	2030-08 (estimated)
Updated on ClinicalTrials.gov	2026-07-24